Pembrolizumab, a humanized IgG4 PD-1 (programmed cell death 1) antagonist antibody, was recently approved for the treatment of advanced melanoma, non–small-cell lung cancer, and head and neck squamous cell carcinoma. As an immune checkpoint inhibitor (CPI), pembrolizumab has a unique toxic effects profile: CPI-induced sarcoidlike reactions are an emerging immune-related adverse event (irAE).1
Burillo-Martinez S, Morales-Raya C, Prieto-Barrios M, Rodriguez-Peralto J, Ortiz-Romero P. Pembrolizumab-Induced Extensive Panniculitis and Nevus Regression: Two Novel Cutaneous Manifestations of the Post-immunotherapy Granulomatous Reactions Spectrum. JAMA Dermatol. 2017;153(7):721–722. doi:10.1001/jamadermatol.2017.0581
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: